[Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report].
Hinyokika Kiyo
; 61(5): 201-5, 2015 May.
Article
em Ja
| MEDLINE
| ID: mdl-26087822
ABSTRACT
A 67-year-old woman underwent radical nephrectomy (clear cell carcinoma, G2ï¼3, pT2b) for left renal cancer with pulmonary metastasis. After interferon-α treatment for 7 months, right iliac bone metastasis occurred. Pulmonary and right ileac bone metastases became larger after 4 months of first sunitinib administration. Replacement by everolimus treatment was not effective. After 6 months of sunitinib rechallenge therapy, pulmonary metastasis disappeared and right ileac bone metastasis became smaller. However, 1 month later, right costal and left femoral metastases occurred. She was kept on sunitinib treatment, and there were no changes in these metastases for 1 year. However, it was difficult to continue sunitinib treatment because of side effects, resulting in growth of metastases. Costal and femoral metastases showed a partial response to axtinib treatment given thereafter. Tyrosine kinase inhibitor rechallenge therapy had potential benefits and was tolerated in selected metastatic renal cell carcinoma patients.
Buscar no Google
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Pulmao
Base de dados:
MEDLINE
Assunto principal:
Pirróis
/
Neoplasias Ósseas
/
Carcinoma de Células Renais
/
Indóis
/
Neoplasias Renais
/
Neoplasias Pulmonares
/
Antineoplásicos
Limite:
Aged
/
Female
/
Humans
Idioma:
Ja
Revista:
Hinyokika Kiyo
Ano de publicação:
2015
Tipo de documento:
Article